Introduction

Neonatal tetanus (NT) is an acute, often fatal disease characterized by generalized, increased rigidity and convulsive spasms of skeletal muscles caused by the spore-forming bacterium Clostridium tetani.

Neonatal tetanus is not transmitted from person to person. The disease is acquired when dirt-containing tetanus spores enter open wounds (injections, cutting the umbilical cord) or breaks in the skin.

The incubation period is 3 to 21 days, with an average of 6 days. It is particularly common in rural areas where deliveries are done at home without adequate sterile procedures. Unclean cord care practices during delivery for neonates and lack of tetanus antibody protection from inadequately immunized mothers are the risk factors for the disease.

Criteria for NT Elimination

- NT Rate of \(<1/1000\) live births
- Quality NT Surveillance (early detection, prompt notification, timely reporting and investigation, at least 80% of Disease Reporting Units (DRUs) are reporting including zero case reporting)
- \(\geq80\%\) Child Protected After Birth (CPAB)
- \(\geq80\%\) Clean delivery
- \(\geq80\%\) Facility-based delivery

Trend in the Philippines

There are 6 clinically confirmed neonatal tetanus cases reported nationwide from January 1 to March 5, 2016. This is 65% lower compared to the same time period last year (17). Of these cases, there were 4 deaths (CFR=66.67).

Fig. 1 Neonatal Tetanus Cases (MW9)

<table>
<thead>
<tr>
<th>REGION</th>
<th>CASES</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>0</td>
</tr>
<tr>
<td>II</td>
<td>1</td>
</tr>
<tr>
<td>III</td>
<td>0</td>
</tr>
<tr>
<td>IV</td>
<td>1</td>
</tr>
<tr>
<td>IVB</td>
<td>0</td>
</tr>
<tr>
<td>V</td>
<td>0</td>
</tr>
<tr>
<td>VI</td>
<td>0</td>
</tr>
<tr>
<td>VII</td>
<td>2</td>
</tr>
<tr>
<td>VIII</td>
<td>0</td>
</tr>
<tr>
<td>IX</td>
<td>0</td>
</tr>
<tr>
<td>X</td>
<td>0</td>
</tr>
<tr>
<td>XI</td>
<td>0</td>
</tr>
<tr>
<td>XII</td>
<td>1</td>
</tr>
<tr>
<td>ARMM</td>
<td>1</td>
</tr>
<tr>
<td>CAR</td>
<td>0</td>
</tr>
<tr>
<td>CAG</td>
<td>0</td>
</tr>
<tr>
<td>NCR</td>
<td>0</td>
</tr>
<tr>
<td>PHL</td>
<td>6</td>
</tr>
</tbody>
</table>

Legend Confirmed
1 dot = 1 case

Geographic Distribution

From January 1 to March 5, 2016, six clinically confirmed NT cases were reported from Regions II, IV-A, VII, XII and ARMM. (Fig. 2)

Profile of Cases

Majority of the clinically confirmed neonatal tetanus cases were male (67%). The age range of NT cases is between 3 to 8 days old. (Fig. 3)
Fig. 1 Clinically Confirmed Neonatal Tetanus Cases by Region
Philippines, January 1 - March 5, 2016 (N=6)

Fig. 2 Clinically Confirmed Neonatal Tetanus Cases by Sex
Philippines, as of March 5, 2016 (N=6)
Fig. 4 Clinically Confirmed Neonatal Tetanus Cases by Agegroup and Sex
Philippines, as of March 5, 2016 (N=6)
- Male
- Female

Fig. 4 Delivery Attendants of Clinically Confirmed Neonatal Tetanus Cases (N=6)
Philippines 2016 (As of MW 9)
- Others* 17%
- Hilot 83%

Fig. 5 Cord Cutting Tool Used in Clinically Confirmed Neonatal Tetanus Cases (N=6)
Philippines 2016 (As of MW 9)
- Others* 17%
- Scissors 50%
- Blade 33%

*self-delivery

*thread
Fig. 6 Stump Treatment Used Among Clinically Confirmed Neonatal Tetanus Cases (N=6) Philippines 2016 (As of MW 9)

- None: 17%
- Alcohol: 50%
- Povidone Iodine: 16%
- Others*: 17%

Fig. 7 Outcome of Clinically Confirmed Neonatal Tetanus Cases (N=6) Philippines 2016 (As of MW 9)

- Alive: 33%
- Died: 67%

Confirmed Neonatal Tetanus Cases & Rate by Province
Philippines, January 1 - March 5, 2016 (N=6)

Fig. 8.1 Region I

Fig. 8.2 Region II

Fig. 8.3 Region III

Fig. 8.4 Region IV-A

A PDF file of this report is available at nec.doh.gov.ph. For more inquiries, you may contact us on the following telephone number: (02) 651-7800 local 2930
Fig. 8.5
Region IV-B

Fig. 8.6
Region V

Fig. 8.7
Region VI

Fig. 8.8
Region VII

Fig. 8.9
Region VIII

Fig. 8.10
Region IX

Fig. 8.11
Region X

Fig. 8.12
Region XI
Neonatal Tetanus Cases

Morbidity Week 9: January 1 - March 5 2016
Epidemiology Bureau
Public Health Surveillance Division

Fig. 8.13 Region XII

Fig. 8.14 ARMM

Fig. 8.15 CAR

Fig. 8.16 CARAGA

Fig. 8.17 NCR
## Neonatal Tetanus Cases

### Table 1 Clinically Confirmed Neonatal Tetanus Case Fatality Rate by Region
Philippines, January 1 - March 5, 2016

<table>
<thead>
<tr>
<th>Region</th>
<th>Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2016</td>
<td>2015</td>
</tr>
<tr>
<td>I</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>II</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>III</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>IVA</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>IVB</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>V</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>VI</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>VII</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>VIII</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>IX</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>X</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>XI</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>XII</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>ARMM</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>CAR</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CRG</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>NCR</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PHL</td>
<td>6</td>
<td>17</td>
</tr>
</tbody>
</table>

### Case Definition

- **Clinically Confirmed Neonatal Tetanus**

  - Any neonate (≤ 28 days of life) that sucks and cries normally during the first 2 days of life, and becomes ill between 3 to 28 days of age and develops both an inability to suck and diffuse muscle rigidity (stiffness) and spasms (jerking of the muscles), which may include trismus, clenched fists or feet, continuously pursed lips, and/or curved back (opisthotonus);

  OR

  - A neonate between 3 to 28 days of life, diagnosed as a case of tetanus by a physician
How can a newborn get it?
- Unhygienic cutting of umbilical cord
- Improper handling of cord stump

How can tetanus be prevented?
- Women of child-bearing age must be immunized by tetanus toxoid
- Clean delivery and cord clumping/cutting must be practiced
- Infants must be immunized with 3 doses of DPT

How can tetanus be treated?
- antibiotics & antitoxin drugs,
- as well as sedatives for muscle spasms

EDITORIAL BOARD

IRMA L. ASUNCION, MD, MHA, CESO IV
Director IV, Epidemiology Bureau

VITO G. ROQUE, JR., RMT, MD, PHSAE
Division Chief, PHSD

Jezza Jonah D. Crucena, RN
National VPD Coordinator

June Cantata B. Corpuz, RN
National PIDSR Program Manager

Allan P. Ignacio
Statistician II

A PDF file of this report is available at nec.doh.gov.ph. For more inquiries, you may contact us on the following telephone number: (02) 652-7800 local 2930